Moreover, the same authors demonstrated that, in NSCLC patients failed to one or more second-generation ALK-i, ALK mutation status revealed by liquid biopsy is predictive of response to treatment with lorlatinib (ORR 62% vs. 32%, for ALK-positive mutation and ALK negative patients, respectively), similar to tissue genotyping (69% vs. 27%) [87]. Here, ALK is linked to non-small cell lung carcinoma.